In non-small cell lung cancer (NSCLC), FSTL3 has been found to be closely associated with angiogenic factors based on bioinformatics studies and may serve as a potential anti-angiogenic therapeutic target (Gu et al., 2022). This evidence concerns the gene FSTL3 and non-small cell lung carcinoma.